Implications of the first FDA-approved anticoagulant in pediatrics: One ship has sailed but the next ones are at the dock.

Szczegóły
Comments

Tytuł:: Implications of the first FDA-approved anticoagulant in pediatrics: One ship has sailed but the next ones are at the dock.
Autorzy:: Young G; Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Źródło:: Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Dec; Vol. 67 (12), pp. e28731. Date of Electronic Publication: 2020 Sep 23.
Typ publikacji:: Journal Article; Comment
Język:: English
Imprint Name(s):: Original Publication: Hoboken, N.J. : John Wiley, c 2004-
MeSH Terms:: Pediatrics*
Venous Thromboembolism*
Anticoagulants ; Child ; Dalteparin ; Humans ; Ships
References:: U.S. Food & Drug Administration. Drug research and children. https://www.fda.gov/drugs/drug-information-consumers/drug-research-and-children. [Accessed September 9, 2020].
Young G, Liesner R, Chang T, et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127-2138.
Merino M, Richardson N, Reaman G, et al. FDA approval summary: dalteparin for the treatment of venous thromboembolism in pediatric patients. Pediatr Blood Cancer. 2020. https://doi.org/10.1002/pbc.28688.
Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer. 2011;57:1049-1054.
Ko RH, Michieli C, Lira JL, Young G. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thromb Res. 2014;134:643-647.
Shen X, Wile R, Young G. FondaKIDS III: a long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children. Pediatr Blood Cancer. 2020;67:e28295.
Yackey K, Stukus K, Cohen D, Kline D, Zhao S, Stanley R. Off-label prescribing practices in pediatrics: an update. Hosp Pediatr. 2019;9:186-193.
Contributed Indexing:: Keywords: FDA; anticoagulation; dalteparin; enoxaparin; fondaparinux; pediatrics
Substance Nomenclature:: 0 (Anticoagulants)
S79O08V79F (Dalteparin)
Entry Date(s):: Date Created: 20200924 Date Completed: 20210118 Latest Revision: 20210118
Update Code:: 20240105
DOI:: 10.1002/pbc.28731
PMID:: 32969168
: Czasopismo naukowe

Full Text Finder

Comment on: Pediatr Blood Cancer. 2020 Dec;67(12):e28688. (PMID: 32896942)

Informacja